201 related articles for article (PubMed ID: 35243415)
21. Advances in the role of heat shock protein 90 in prostate cancer.
Fu Z; Jia B
Andrologia; 2022 May; 54(4):e14376. PubMed ID: 35075667
[TBL] [Abstract][Full Text] [Related]
22. Fatty Acid Oxidation Is an Adaptive Survival Pathway Induced in Prostate Tumors by HSP90 Inhibition.
Nassar ZD; Mah CY; Centenera MM; Irani S; Sadowski MC; Scott JS; Nguyen EV; Nagarajan SR; Moldovan M; Lynn DJ; Daly RJ; Hoy AJ; Butler LM
Mol Cancer Res; 2020 Oct; 18(10):1500-1511. PubMed ID: 32669400
[TBL] [Abstract][Full Text] [Related]
23. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer.
Kang BH; Siegelin MD; Plescia J; Raskett CM; Garlick DS; Dohi T; Lian JB; Stein GS; Languino LR; Altieri DC
Clin Cancer Res; 2010 Oct; 16(19):4779-88. PubMed ID: 20876793
[TBL] [Abstract][Full Text] [Related]
24. Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms.
Centenera MM; Carter SL; Gillis JL; Marrocco-Tallarigo DL; Grose RH; Tilley WD; Butler LM
Endocr Relat Cancer; 2015 Oct; 22(5):805-18. PubMed ID: 26187127
[TBL] [Abstract][Full Text] [Related]
25. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
[TBL] [Abstract][Full Text] [Related]
26. Hsp90 inhibitor 17-AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance.
O'Malley KJ; Langmann G; Ai J; Ramos-Garcia R; Vessella RL; Wang Z
Prostate; 2012 Jul; 72(10):1117-23. PubMed ID: 22161776
[TBL] [Abstract][Full Text] [Related]
27. Combination of rapamycin, CI-1040, and 17-AAG inhibits metastatic capacity of prostate cancer via Slug inhibition.
Ding G; Feng C; Jiang H; Ding Q; Zhang L; Na R; Xu H; Liu J
PLoS One; 2013; 8(10):e77400. PubMed ID: 24130883
[TBL] [Abstract][Full Text] [Related]
28. The co-chaperone p23 promotes prostate cancer motility and metastasis.
Cano LQ; Lavery DN; Sin S; Spanjaard E; Brooke GN; Tilman JD; Abroaf A; Gaughan L; Robson CN; Heer R; Mauri F; de Rooij J; Driouch K; Bevan CL
Mol Oncol; 2015 Jan; 9(1):295-308. PubMed ID: 25241147
[TBL] [Abstract][Full Text] [Related]
29. Hsp90: still a viable target in prostate cancer.
Centenera MM; Fitzpatrick AK; Tilley WD; Butler LM
Biochim Biophys Acta; 2013 Apr; 1835(2):211-8. PubMed ID: 23287571
[TBL] [Abstract][Full Text] [Related]
30. The dietary bioflavonoid, quercetin, selectively induces apoptosis of prostate cancer cells by down-regulating the expression of heat shock protein 90.
Aalinkeel R; Bindukumar B; Reynolds JL; Sykes DE; Mahajan SD; Chadha KC; Schwartz SA
Prostate; 2008 Dec; 68(16):1773-89. PubMed ID: 18726985
[TBL] [Abstract][Full Text] [Related]
31. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells.
Liu W; Vielhauer GA; Holzbeierlein JM; Zhao H; Ghosh S; Brown D; Lee E; Blagg BS
Mol Pharmacol; 2015 Jul; 88(1):121-30. PubMed ID: 25939977
[TBL] [Abstract][Full Text] [Related]
32. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
33. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
[TBL] [Abstract][Full Text] [Related]
34. Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer.
Chen L; Li J; Farah E; Sarkar S; Ahmad N; Gupta S; Larner J; Liu X
Mol Cancer Ther; 2016 Sep; 15(9):2107-18. PubMed ID: 27390342
[TBL] [Abstract][Full Text] [Related]
35. Cell Stress Induced Stressome Release Including Damaged Membrane Vesicles and Extracellular HSP90 by Prostate Cancer Cells.
Eguchi T; Sogawa C; Ono K; Matsumoto M; Tran MT; Okusha Y; Lang BJ; Okamoto K; Calderwood SK
Cells; 2020 Mar; 9(3):. PubMed ID: 32204513
[TBL] [Abstract][Full Text] [Related]
36. Ultrasound-targeted microbubble destruction combined with dual targeting of HSP72 and HSC70 inhibits HSP90 function and induces extensive tumor-specific apoptosis.
Wang H; Song Y; Hao D; Bai M; Jin L; Gu J; Su Y; Liu L; Jia C; Du L
Int J Oncol; 2014 Jul; 45(1):157-64. PubMed ID: 24736948
[TBL] [Abstract][Full Text] [Related]
37. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease.
Kang BH; Tavecchio M; Goel HL; Hsieh CC; Garlick DS; Raskett CM; Lian JB; Stein GS; Languino LR; Altieri DC
Br J Cancer; 2011 Feb; 104(4):629-34. PubMed ID: 21285984
[TBL] [Abstract][Full Text] [Related]
38. Effect of the hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions.
Suzuki Y; Kondo Y; Hara S; Kimata R; Nishimura T
Int J Urol; 2010 Mar; 17(3):281-5. PubMed ID: 20409220
[TBL] [Abstract][Full Text] [Related]
39. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
[TBL] [Abstract][Full Text] [Related]
40. Capsaicin binds the N-terminus of Hsp90, induces lysosomal degradation of Hsp70, and enhances the anti-tumor effects of 17-AAG (Tanespimycin).
Patwardhan CA; Kommalapati VK; Llbiyi T; Singh D; Alfa E; Horuzsko A; Korkaya H; Panda S; Reilly CA; Popik V; Chadli A
Sci Rep; 2023 Aug; 13(1):13790. PubMed ID: 37612326
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
